Retinal Disorders/Ocular Specialty Enrollment Form



Fax Referral To: 1-855-297-1270 Phone: 1-888-280-1190

Address: 6020 Ave Roberto Sanchez Vilella Carolina, PR 00982 NCPDP: 4026325

	omplete or include demographic sheet)					
Patient Name:		DOR.	Go	nder: 🗌 Male 🔲 Female		
Address:	City, State, ZIP (Codo:	Ge	nder. Iviale Terriale		
Preferred Contact Methods Ph	none (to primary # provided below)	ext (to cell # nr	ovided below)	Temail (to email provided		
pelow)	one (to primary # provided below) [1	ext (to cell # pro	ovided below)	_ Linait (to emait provided		
<i>,</i>	By providing the phone number(s) and er	mail addrace ab	ava vou ara can	conting to receive		
	xt messages from CVS Specialty® about y					
	aries. If unable to contact via text or ema					
			-			
=nmary =none =mail:	ary Phone: Alternate Phone: Primary Language: last Four of SSN: Primary Language:					
	ver/Guardian Name (Last, First):Last Four of SSN Frimary Language					
		Re	tationship to pa	ment:		
PRESCRIBER INFORMATION						
	s					
NPI #: DEA #:	Group or Hospital:					
Address:	City, Star	te, ZIP Code:				
	x Contact Person:					
INSURANCE INFORMATION	Please fax copy of prescription and insurance care	ds with this form, if a	available (front and b	ack)		
DIAGNOSIS AND CLINICAL						
Needs by Date:	Ship to: 🗌 P	atient 🗌 Office	Other:	· · · · · · · · · · · · · · · · · · ·		
Diagnosis (ICD-10):						
CD-10 Code: Diagr	nosis: Affe	cted eye(s):	Right Eye Le	ft Eye 🔲 Both Eyes		
Patient Clinical Information:		-		-		
Allergies:	Height:	in/cm	Weight:	lb./kg		
Ourysta: Can only be used once p			0	0		
	$urysta$ implant in the treatment eye? \square	Yes No				
luvien:		_				
Prior corticosteroid treatment req	uired per the FDA labeled indication for	Iluvien:				
-	Date					
-	_					
Susvimo:		elial growth fact	or (VEGF) inhibit			
Susvimo : Previous response to at least 2 intr	ravitreal injections of a vascular endothe	elial growth fact	or (VEGF) inhibit			
Gusvimo : Previous response to at least 2 intr per the FDA labeled indication for	ravitreal injections of a vascular endothe	_		or medication are required		
Susvimo: Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da	te prescribed _		or medication are required		
Susvimo: Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da: Da:	te prescribed _		or medication are required		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da Da ION	te prescribed _ te prescribed _		or medication are required		
Susvimo: Previous response to at least 2 introper the FDA labeled indication for Medication prescribed PRESCRIPTION INFORMAT	ravitreal injections of a vascular endothe Susvimo: Da Da DOSE & D	te prescribed _		or medication are required		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da: Da: ION DOSE & D Induction dose: Inject 6 mg monthly for the first	te prescribed _ te prescribed _ IRECTIONS		or medication are required		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da: Da: ION DOSE & D Induction dose: Inject 6 mg monthly for the first	te prescribed _ te prescribed _ IRECTIONS		or medication are required Output QUANTITY/REFILLS		
Previous response to at least 2 introver the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da Da ION DOSE & D Induction dose:	te prescribed _ te prescribed _ IRECTIONS		or medication are required QUANTITY/REFILLS Quantity:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da: Da: DOSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for the	te prescribed _ te prescribed _ IRECTIONS		or medication are required Output QUANTITY/REFILLS		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da Da Da ION DOSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for th Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks.	te prescribed _ te prescribed _ IRECTIONS three doses. the first five doses.		or medication are required QUANTITY/REFILLS Quantity:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Da Da DoSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for th Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other:	te prescribed _ te prescribed _ IRECTIONS three doses. the first five doses.		or medication are required QUANTITY/REFILLS Quantity: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Date	te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injections		QUANTITY/REFILLS Quantity: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	Induction dose: Inject 6 mg every 6 weeks for the Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel)	te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injections		or medication are required QUANTITY/REFILLS Quantity: Refills:		
Previous response to at least 2 introver the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endothe Susvimo: Date	te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injects and the prescribed y 28 days)	ection into affected	QUANTITY/REFILLS Quantity: Refills: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed	Inject 6 mg every 6 weeks for the Other: Dailon Dose Description Dose Description	te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injects and the prescribed y 28 days)	ection into affected	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills:		
Previous response to at least 2 intributed in the FDA labeled indication for Medication prescribed	ravitreal injections of a vascular endother Susvimo: Da: Da: ION DOSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for the Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel Other: Dose: Dose:	te prescribed _ te prescribed _ IRECTIONS three doses. the first five doses. by intravitreal injury 28 days)	ection into affected	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed Medication prescribed PRESCRIPTION INFORMAT MEDICATION STRENGTH Beovu	ravitreal injections of a vascular endother Susvimo: Da: Da: Dos: Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for th Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel Other: Dose: Dose:	te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injury 28 days)	ection into affected	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed Medication prescribed PRESCRIPTION INFORMAT MEDICATION STRENGTH Vial PFS Description Strength Description Prescription Strength Prescription Prescr	ravitreal injections of a vascular endother Susvimo: Da Da Da ION Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for the Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel Other: Dose: STAMP SIGNATURE NOT ALL RIBER SIGNATURE REQUIRED (STA	te prescribed te prescribed te prescribed IRECTIONS three doses. three dos	ection into affected Ancillary supplies and RE NOT ALLO	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills: Refills: Quantity: Refills: Quantity: Refills: Refills: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed Medication prescribed PRESCRIPTION INFORMAT MEDICATION STRENGTH Vial PFS 0.5 mg single-ovial Other: Strength: Patient is interested in patient support program PRESCRIPTION PRES	ravitreal injections of a vascular endother Susvimo: Da: Da: ION DOSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for the Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel Other: Dose: STAMP SIGNATURE NOT ALLE RIBER SIGNATURE REQUIRED (STA) Cessary / Do Not Substitute / No Substitution /	te prescribed te prescribed te prescribed IRECTIONS three doses. three dos	ection into affected Ancillary supplies and RENOT ALLO ct Selection Permitted	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills: Refills: Quantity: Refills: Quantity: Refills: Refills: Refills:		
Previous response to at least 2 introper the FDA labeled indication for Medication prescribed Medication prescribed PRESCRIPTION INFORMAT MEDICATION STRENGTH Vial PFS Dispense As Written" / Brand Medically Necessity Dispense As Written" / Brand Medically Necessity Dispense As Written" / Brand Medically Necessity Per at least 2 introduction at least 2 introduction for medical particular and prescribed in the presc	ravitreal injections of a vascular endother Susvimo: Da: DOSE & D Induction dose: Inject 6 mg monthly for the first Inject 6 mg every 6 weeks for the Other: Maintenance dose: Inject 6 mg every 8 to 12 weeks. Other: Prepare and administer 0.5 mg eye(s) once a month (approximatel Other: Dose: STAMP SIGNATURE NOT ALLE RIBER SIGNATURE REQUIRED (STA) Cessary / Do Not Substitute / No Substitution / M. Substitute / No Substitute / No Substitution / M. Substitute / No Substitute	te prescribed te prescribed te prescribed IRECTIONS three doses. the first five doses. by intravitreal injury 28 days) OWED MP SIGNATU ay Substitute / Produ	ection into affected Ancillary supplies and RENOT ALLO ct Selection Permitted	QUANTITY/REFILLS Quantity: Refills: Quantity: Refills: Quantity: Refills: Quantity: Refills: Quantity: Refills:		

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

Retinal Disorders/Ocular Specialty Enrollment Form

Dotiont Name:	-		Prescriber Information				
Patient Name: Patient Address: ₋	Pre		Patient Phone: Prescriber Phone:				
Patient Address:Prescriber Name:Prescriber Phone:Prescriber Phone:Prescriber Phone:							
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS			
☐ Cimerli	0.3 mg/0.05 mL single-dose vial 0.5 mg/0.05 mL single-dose vial	affected eye(s) once Prepare and adn	ninister 0.3 mg by intravitreal injection into e a month (approximately 28 days) ninister 0.5 mg by intravitreal injection into e a month (approximately 28 days)	Quantity: Refills:			
Durysta	1 applicator	☐ To be injected by ☐ Other:	y physician as directed	Quantity:			
☐ Eylea	☐ Vial	☐ Inject 2 mg (0.05 mL) every 4 weeks (monthly) for the first 3 injections followed by 2 mg (0.05 mL) once every 8 weeks. ☐ Inject 2 mg (0.05 mL) every 12 weeks (3 months) after one year of effective therapy with regular assessment. ☐ Inject 2 mg (0.05 mL) every 4 weeks (monthly) for the first 5 injections followed by 2 mg (0.05 mL) once every 8 weeks. ☐ Inject 2 mg (0.05 mL) every 4 weeks (monthly) ☐ Pediatric - Inject 0.4mg (0.01mL) ☐ Other:		Quantity: Refills:			
☐ Eylea HD	☐ 8mg	☐ Inject 8 mg every 4 weeks (monthly) for the first 3 injections followed by 8 mg every 8 to 16 weeks (2 to 4 months) ☐ Inject 8 mg every 4 weeks (monthly) for the first 3 injections followed by every 8 to 12 weeks (2 to 3 months) ☐ Other:		Quantity: Refills:			
☐ Iluvien	1 applicator	To be injected by Other:	y physician as directed	Quantity:			
☐ Izervay	2 mg single-dose vial (0.1 mL of 20 mg/mL solution)	Prepare and administer 2 mg by intravitreal injection into each affected eye once monthly (approximately 28 days) Other:		Quantity: Refills:			
Lucentis	0.3 mg/0.05 mL single-dose PFS 0.3 mg/0.05 mL single-dose vial 0.5 mg/0.05 mL single-dose PFS 0.5 mg/0.05 mL single-dose vial	Prepare and adn affected eye(s) once Prepare and adn affected eye(s) once	Quantity: Refills:				
Ozurdex	1 applicator	To be injected by	Quantity: Refills:				
Retisert	1 implant	☐ To be implanted by physician as directed☐ Other:		Quantity:			
Susvimo	1 Refill Kit	To be injected by physician as directed Other:		Quantity: Refills:			
☐ Vabysmo	☐ 6 mg	☐ To be injected by physician as directed ☐ Other:		Quantity: Refills:			
Visudyne	☐ Vial	☐ To be infused by physician as directed ☐ Other:		Quantity: Refills:			
☐ Xdemvy	0.25%	☐ Instill one drop in each eye twice daily (approximately 12 hours apart) for 6 weeks ☐ Other:		Quantity: Refills:			
Other:	Strength:	Dose:		Quantity: Refills:			
Patient is interested	d in patient support programs PRESCRIBER SIGNATU	STAMP SIGNATURE NOT	TALLOWED Ancillary supplies and kits provid TAMP SIGNATURE NOT ALLOWED)	led as needed for administration			
DAW / May Not Su Prescriber's S	ten" / Brand Medically Necessary / Do Not Substit bstitute Signature:	ute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: ATTN: New York and Iowa providers, plants	Date:ease submit electronic prescription			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.